We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH). It conducts research, development, and... Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH). It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles designed to improve the safety, efficacy, and performance of a wide range of therapies. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. Show more
MORRISVILLE, N.C., May 13, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today reported financial results for the first quarter ended March 31, 2024. The company will host a...
MORRISVILLE, N.C., May 10, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today the company will present data related to the investigational use of L606 (liposomal...
MORRISVILLE, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Michael Kaseta, chief operating officer and chief financial officer, will provide an...
MORRISVILLE, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its first quarter 2024 financial results on May 14, 2024. The company...
MORRISVILLE, N.C., April 02, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced today that Dr. Roger Jeffs, Chief Executive Officer, and Micheal...
On March 28, Judge Andrews removed the injunction issued in the Original Hatch Waxman LitigationOn March 29, Judge Bates denied United Therapeutics’ motion for temporary restraining order and...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.39 | 3.15789473684 | 12.35 | 13.04 | 11.65 | 733522 | 12.23760465 | CS |
4 | -0.94 | -6.87134502924 | 13.68 | 13.97 | 11.65 | 763049 | 12.67538265 | CS |
12 | -1.32 | -9.38833570413 | 14.06 | 16.99 | 11.65 | 817841 | 14.14775912 | CS |
26 | 6.37 | 100 | 6.37 | 16.99 | 6.19 | 1034503 | 12.33343966 | CS |
52 | 5.22 | 69.414893617 | 7.52 | 16.99 | 5.71 | 776807 | 10.65310526 | CS |
156 | 10 | 364.96350365 | 2.74 | 16.99 | 2.25 | 764117 | 7.17424971 | CS |
260 | 2.91 | 29.6032553408 | 9.83 | 16.99 | 2.25 | 651296 | 6.22855375 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions